Bosutinib is a selective dual Abl/Src inhibitor used in chronic myeloid leukemia (CML) to inhibit the Bcr-Abl fusion protein. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.